June 23, 2026

‍

Kymera Therapeutics, Inc. (NASDAQ: KYMR) disclosed that director Bruce Booth sold approximately $48.6 million worth of company shares, according to Form 4 filings with the U.S. Securities and Exchange Commission (SEC).
‍

The reported sales occurred between June 17 and June 22, 2026. Booth sold 116,812 shares on June 17 at an average price of $90.34, 115,056 shares on June 18 at an average price of $91.01, 246,330 shares on June 22 at an average price of $98.52, and another 31,798 shares on June 22 at an average price of $103.75.
‍

In total, the filings show 509,996 shares sold across four reported transactions.
‍

Kymera Therapeutics is a biotechnology company developing targeted protein degradation therapies for immune-inflammatory diseases and oncology.

‍

Director Sale Above $48M Draws Attention

‍

The sale activity is notable because it is far above typical insider-selling thresholds.
‍

Single insider sales above $1 million are generally worth reviewing, while sales above $5 million tend to draw greater investor attention.
‍

In this case, Booth’s reported sales totaled approximately $48.6 million across several trading days.

‍

Selling Accelerated on June 22

‍

The largest portion of the reported selling occurred on June 22.
‍

Booth sold 246,330 shares at an average price of $98.52 for approximately $24.3 million. A separate June 22 filing showed an additional sale of 31,798 shares at an average price of $103.75 for approximately $3.3 million.
‍

Together, the June 22 transactions accounted for about $27.6 million of the total reported sale value.

‍

Remaining Ownership Requires Careful Reading

‍

The filings show the transactions were reported through indirect ownership.
‍

After the latest reported sale, one listed indirect position showed 613,762 shares owned. The Form 4 also included other indirect ownership lines, so the reported share count should be read in the context of the specific ownership vehicle tied to each transaction.
‍

That means the filing should be framed as a large director sale, not necessarily a complete exit.

‍

Context: Planned Sale Lowers the Signal Strength

‍

The Form 4 filings indicate that the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1 conditions.
‍

That lowers the signal strength compared with discretionary open-market selling.
‍

Insider selling can reflect diversification, liquidity planning, tax planning, or pre-arranged trading programs. Still, the size of the sale makes the filings relevant for investors tracking insider activity.

‍

The Bigger Picture: Large Director Sales Require Context

‍

Large insider sales become more meaningful when they exceed common dollar thresholds, occur across multiple filings, or reduce reported ownership over a short period.
‍

Platforms like LevelFields track insider transactions alongside other market-moving events, helping investors identify when insider selling exceeds key thresholds and may signal a meaningful shift in ownership behavior.